Acute Myeloid Leukemia (AML) - Pipeline Assessment, 2023 Updates | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, and Treatment Outlook | Abbvie, Bristol-Myers Squibb, Gilead Sciences, Sanofi

As per Global Insight services' assessment, about 200+ prominent pharma and biotech giants are working on 200+ drugs in the Acute Myeloid Leukemia (AML) - pipeline landscape globally. Acute Myeloid Leukemia (AML) Pipeline Insight, 2023" report by Global Insight Services provides a comprehensive analysis of the ongoing clinical development activities and growth prospect.

Download PDF Sample Pages to Get an in-depth Assessment of the Emerging Therapies and Key Companies: https://www.globalinsightservices.com/request-sample/GIS31261

Acute Myeloid Leukemia (AML, Acute Myeloblastic Leukemia) is a type of blood cancer in which the bone marrow produces a large number of abnormal blood cells which is also called as Acute Myeloid Leukemia, Acute Granulocytic Leukemia and Acute Nonlymphocytic Leukemia.

The most common causes of Acute Myeloid Leukemia are mutations in the DNA, smoking, previous chemotherapy treatment, exposure to radiation, hazardous chemical exposure, age, other genetic or blood disorders. The most common symptoms of Acute Myeloid Leukemia include fever, fatigue, paleness or loss of normal skin color, unusual bleeding/ bruises, frequent infections, headache, weight loss, shortness of breath etc.

Acute Myeloid Leukemia can be diagnosed by the doctors by a physical exam to look for signs of bleeding, bruising, or infection. Diagnostic tests include Blood tests, Imaging tests, Bone marrow tests, Spinal tap, Genetic tests etc.
The most common treatments for Acute Myeloid Leukemia are chemotherapy, radiotherapy, stem cell transplantation, targeted therapy with either or combinations as remission induction therapy and consolidation therapy.

Read more about Acute Myeloid Leukemia (AML) Pipeline Insight here: https://www.globalinsightservices.com/reports/acute-myeloid-leukemia-aml-drug-pipeline-landscape/

Report Highlights:

Global Insight Service's, "Acute Myeloid Leukemia (AML) - Drug Pipeline Landscape, 2023," is an overview of the Acute Myeloid Leukemia pipeline drugs. This report covers detailed insights on Acute Myeloid Leukemia drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to gain insights and thus help industry participants for decision making.

Methodology:

The research process includes extensive secondary research on public domain and other authentic sources carried out to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, clinical trials registries.

Scope:

The pipeline landscape report consists of pipeline product based on several stages of development ranging from discovery to Pre-Registration. The report provides a review of pipeline therapeutics for Acute Myeloid Leukemia by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of Acute Myeloid Leukemia therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals and key upcoming milestones.

For In-Depth Competitive Analysis, Purchase this Report: https://www.globalinsightservices.com/checkout/single_user/GIS31261

Key Players:

• 2seventy bio
• AB Science
• AbbVie
• ABL Bio
• Actinium Pharmaceuticals
• ADC Therapeutics S.A.
• Advanced BioDesign
• Affimed N.V.
• Agastiya Biotech
• Akeso

Report Covers the Emerging Pipeline Products Under Different Phases of Clinical Development Like:

- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates

Contact Us:

Global Insight Services LLC
16192, Coastal Highway, Lewes DE 19958
E-mail: info@globalinsightservices.com
Phone: +1-833-761-1700

About Global Insight Services:

Global Insight Services (GIS) is a leading multi-industry market research firm headquartered in Delaware, US. We are committed to providing our clients with highest quality data, analysis, and tools to meet all their market research needs. With GIS, you can be assured of the quality of the deliverables, robust & transparent research methodology, and superior service.

This release was published on openPR.